A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol

Contraception

Volumn 53, Issue 2, 1996, Pages 75-84

  Winkler, U H ^a   Schindler, A E ^a   Endrikat, Jan ^b   Dusterberg B ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

ethinylestradiol; gestodene; hemostasis; oral contraceptive

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; ETHINYLESTRADIOL; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VEIN OCCLUSION;

EID: 0030021994     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(95)00271-5     Document Type: Article

References (30)

1. Meade TW, Haines AP, North RWS et al. Haemostatic, lipid and blood pressure profiles of women on oral contraceptives containing 50 μg or 30 μg of oestrogen. Lancet 1977;88:948-51.
2. Bruni V, Bucciantini S, Rosati D et al. Long term study of the effects of a combination of cyproterone acetate and ethinylestradiol on the haemostatic system. Fortschr Med 1987;3:51-6.
3. Fortherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994;49:1-32.
4. Daly I, Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am J Obstet Gynecol 1990;163:430-7.
5. Winkler UH, Koslowski S, Schindler AE. PAI activity is reduced in users of oral contraceptives - influence of estrogen content. Thromb Haemost 1989;62:394.
6. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-8.
7. Sabra A, Bonnar J. Hemostatic changes induced by 50 μg and 30 μg estrogen/progestogen oral contraceptives. J Reprod Med 1983;28:85-91.
8. Bottiger LE, Boman G, Eklund G, Westerholme B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;i:1097-101.
9. Meade TW, Greenberg G, Thrompson SC. Progestogens and cardiovascular reactions associated with oral contraceptives and comparison of the safety of 50 and 30 μg oestrogen preparations. Br Med J 1980;i:1157-61.
10. Kierkegaard A, Deep-vein thrombosis and the oestrogen content in oral contraceptives. Annual epidemiological analysis. Contraception 1985;31:29-41.
11. Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990;163:396-403.
12. Winkler UH, Bühler K, Schindler AE. The dynamic balance of hemostasis: implications for the risk of oral contraceptive use. In: Runnebaum B, Rabe T, eds. Female contraception and male fertility regulation. Carnforth, UK: Parthenon Publishing, 1991:85-92.
13. Winkler UH. Hemostasis in oral contraception: the role of progestogens. Gynecol Endocrinol 1993;7(Suppl):59-64.
14. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis. Thromb Haemost 1988;60:361-4.
15. Pizzo SV, Lewis JG, Campbell EE, Dreyer NA. Fibrinolytic response and oral contraceptive-associated thromboembolism. Contraception 1981;23:181-6.
16. Jespersen J, Bertina RM, Haverkate F, eds. ECTA assay procedures. A manual of laboratory techniques. London: Kluwer Academic Publishers, 1992.
17. Juhan-Vague I, Valadier J, Alessi MC et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep vein thrombosis. Thromb Haemost 1987;57:67-72.
18. Clauss A. Gerinnungsphysiologische Shnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17:237-46.
19. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin III complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990; 74:471-9.
20. Gerstman BB, Piper JM, Tomita DK et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133: 32-7.
21. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
22. Trauchst-Van Horn JJ, Capeless EL, Easterling TR, Bovill EG. Pregnancy loss and thrombosis with protein C deficiency. Am J Obstet Gynecol 1992;167:9968-72.
23. Nilsson IM, Ljungner H, Tjengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985;290:1453-8.
24. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987;70:343-8.
25. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study. Thromb Haemost 1994;71:441-5.
26. Daume E. Influence of modern low-dose oral contraceptives on hemostasis. Adv Contracept 1990;6(Suppl):51-68.
27. Melis GB, Fruzzeti F, Nicoletti I, Ricci C, Lammers P, Atsma WJ, Fioretti P. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991;43:23-31.
28. Winkler UH, Koslowski S, Oberhoff C, Schindler EM, Schindler AE. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate-containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv Contracept 1991; 7:273-84.
29. Pabinger I, Schneider B and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C-and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994;71:548-52.
30. Comp PC, Zacur HA. Contraceptive choices in women with coagulation disorders. Am J Obstet Gynecol 1993; 168:2042-8.